Boston Trust Walden Corp Sells 69,618 Shares of Zoetis Inc. $ZTS

Key Points

• Boston Trust Walden cut its Zoetis stake by 63.6% in the third quarter, selling 69,618 shares and retaining 39,769 shares valued at about $2.8 million.
• Zoetis beat quarterly earnings and revenue estimates, reporting EPS of $1.75 and revenue of $2.39 billion, and raised its 2026 profit outlook. However, revenue fell 1.3% year over year amid softness in companion-animal products.
• Analysts’ consensus rating is Hold, with an average price target of $101.25; the company also announced a quarterly dividend of $0.53 per share.

Boston Trust Walden Corp trimmed its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 63.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,769 shares of the company's stock after selling 69,618 shares during the period. Boston Trust Walden Corp's holdings in Zoetis were worth $2,777,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Ascent Group LLC lifted its position in Zoetis by 31.7% in the third quarter. Ascent Group LLC now owns 14,310 shares of the company's stock valued at $999,000 after purchasing an additional 3,444 shares during the last quarter. Kelleher Financial Advisors raised its holdings in Zoetis by 239.2% during the 3rd quarter. Kelleher Financial Advisors now owns 563 shares of the company's stock valued at $39,000 after buying an additional 397 shares during the last quarter. Markel Group Inc. raised its holdings in Zoetis by 542.5% during the 3rd quarter. Markel Group Inc. now owns 425,296 shares of the company's stock valued at $29,698,000 after buying an additional 359,101 shares during the last quarter. Parr Mcknight Wealth Management Group LLC boosted its position in Zoetis by 9.2% during the 3rd quarter. Parr Mcknight Wealth Management Group LLC now owns 21,501 shares of the company's stock valued at $1,501,000 after buying an additional 1,811 shares during the period. Finally, Provenance Wealth Advisors LLC grew its holdings in Zoetis by 1,866.7% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 531 shares of the company's stock worth $37,000 after acquiring an additional 504 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on ZTS shares. William Blair downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating in a research note on Thursday, August 6th. BNP Paribas Exane cut their target price on Zoetis from $146.00 to $110.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 11th. The Goldman Sachs Group assumed coverage on Zoetis in a report on Friday, October 16th. They set a "neutral" rating and a $74.00 price target on the stock. Cantor Fitzgerald set a $94.00 price target on Zoetis in a research report on Tuesday, August 25th. Finally, Morgan Stanley dropped their price objective on Zoetis from $85.00 to $82.00 and set an "overweight" rating for the company in a report on Thursday, October 29th. Eight equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $101.25.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Adjusted EPS of $1.75 topped the $1.51 consensus, while revenue of $2.39 billion exceeded expectations of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
• Positive Sentiment: Livestock revenue grew 7% to $797 million, helping offset softness in companion-animal products. Jefferies also raised its price target to $85 from $83. Zoetis: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Investors appear focused on ongoing pressure in the pet-health business: owners are cutting back on veterinary visits, and Zoetis is taking a cautious view of 2027. Competitive pressures and margin headwinds also weigh on the outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall ZTS Q3 2026 deep dive: Competitive pressures and margin headwinds weigh on outlook
• Negative Sentiment: Despite beating estimates, quarterly revenue declined 1.3% year over year, reinforcing concerns that strength in livestock may not fully offset weaker companion-animal demand. Zoetis reports third-quarter results

Zoetis Price Performance

Shares of NYSE ZTS opened at $79.50 on Friday. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company's 50-day moving average is $75.68 and its 200 day moving average is $92.60. The stock has a market capitalization of $32.85 billion, a P/E ratio of 13.52, a P/E/G ratio of 1.23 and a beta of 0.67.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.51 by $0.24. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the firm earned $1.70 earnings per share. Zoetis's revenue was down 1.3% on a year-over-year basis. On average, sell-side analysts expect that Zoetis Inc. will post 6.15 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, October 30th. Zoetis's dividend payout ratio (DPR) is presently 34.93%.

About Zoetis

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company's offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer's animal health business and became an independent public company in 2013.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.